Emergency Medicine Unit and European Society of Hypertension Specialized Center of Excellence for Hypertension, Department of Medicine-DIMED, University of Padua, Padova, Italy.
Molecular Internal Medicine, University of Zürich, and Andreas Grüntzig Foundation, Zürich, Switzerland.
J Hypertens. 2023 Mar 1;41(3):369-379. doi: 10.1097/HJH.0000000000003314. Epub 2022 Dec 22.
Endothelial cell function is mediated by different mechanisms in different vascular beds. Moreover, in humans, endothelial cell dysfunction triggers and accelerates the progression of cardiovascular and chronic kidney diseases. Progression of such diseases can be in part mitigated by the control of cardiovascular risk factors and drugs targeting different systems, including endothelin receptor antagonists (ERAs), renin-angiotensin aldosterone antagonists and agents affecting glucose metabolism, all of which were shown to improve endothelial cell function. In recent years, the microRNAs, which are endogenous regulators of gene expression, have been identified as transmitters of information from endothelial cells to vascular smooth muscle cells, suggesting that they can entail tools to assess the endothelial cell dysfunction in arterial hypertension and target for pharmacologic intervention. This article critically reviews current challenges and limitations of available techniques for the invasive and noninvasive assessment of endothelial cell function, and also discusses therapeutic aspects as well as directions for future research in the areas of endothelial cell biology and pathophysiology in humans.
内皮细胞功能通过不同的机制在不同的血管床中发挥作用。此外,在人类中,内皮细胞功能障碍触发并加速了心血管疾病和慢性肾脏病的进展。通过控制心血管危险因素和针对不同系统的药物(包括内皮素受体拮抗剂、肾素-血管紧张素-醛固酮拮抗剂和影响葡萄糖代谢的药物)可以部分减轻这些疾病的进展,这些药物都被证明可以改善内皮细胞功能。近年来,内源性基因表达调节剂 microRNA 被确定为内皮细胞向血管平滑肌细胞传递信息的介质,提示它们可以作为评估动脉高血压内皮细胞功能障碍的工具,并作为药理学干预的靶点。本文批判性地回顾了目前用于评估内皮细胞功能的有创和无创技术的挑战和局限性,并讨论了治疗方面以及人类内皮细胞生物学和病理生理学领域未来研究的方向。